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Introduction
H
epatocellular carcinoma (HCC), a malignant 
tumor originating from hepatocytes, is the 
sixth-most prevalent cancer worldwide. Furthermore, 
due to its poor prognosis, it is also the fourth leading 
cause of death related to cancer (1). Although HCC 
is not generally common, it is an intractable disease 
(2). Therefore, we have to pay special attention to the 
risk factors of HCC in order to decrease its burden 
on society. There is a great variation in the incidence 
of HCC between and even within countries. These 
differences might be due to regional variations in 
exposure to HCC risk factors. The annual incidence 
of HCC has been estimated to be high in Africa 
(24/100,000) and eastern areas of Asia (35/100,000); 
whereas its incidence is low in North America, Western 
Europe,  and  the  Middle  East  (3-4/100,000)  (3). 
Although Iran is located in a low-risk region with 
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Background and Aims: Hepatocellular carcinoma (HCC) is a well-known consequence of chronic liver disease (CLD). The 
aim of this study was to extract the HCC incidence rate in the province of Kerman, located in southern part of Iran, and 
compare the data with other parts of the country.
Materials and Methods: All medical records related to HCC were collected through hospitals or outpatient services in 
public or private centers. The records of all oncology, radiotherapy, and pathology centers in Kerman province were 
actively searched between 1999 and 2006. The annual incidence of HCC around the country was calculated, using the 
national cancer registry database provided by the Health Ministry of IR Iran from 2005 to 2006. Using Stata version 8, 
the crude and age-sex-standardized annual incidence rates were computed.
Results: The crude annual incidence rates of HCC per 100,000 persons in Kerman and Iran were 0.522 (95% CI = 0.238-
0.88) and 0.199 (95% CI = 0.167-0.234), respectively. When adjusting for age and sex, the annual incidence rates of HCC 
in Kerman and Iran were 0.7 (95% CI = 0.4-1.1) and 0.2 (95% CI = 0.2-0.3) per 100,000 persons, respectively (P<0.01).   
The mean age of patients in Kerman was around 5.5 years younger than other parts of Iran (56.17 ± 18.32 years versus 
61.68 ± 14.62 years; P=0.004).
Conclusions: In general, the incidence of HCC is not very high in Iran; however, the higher incidence of HCC in Kerman 
and also the lower age of onset mandates further research to detect HCC’s risk factors in this part of country.
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an annual incidence well under 5 per 100,000 (2), 
we  could  not  find  specific  information  about  its 
distribution within the country. Because the main 
known HCC risk factors vary around the country, it 
is reasonable to presume that its incidence also varies 
significantly.
Some of the potent risk factors of HCC are now 
well-documented and include chronic viral hepatitis, 
cirrhosis, alcohol abuse, and Aflatoxin exposure (4). 
However, other risk factors, such as smoking, obesity, 
and diabetes, are also associated with increased risk of 
HCC (5, 6). We did not find any specific information 
about the epidemiology of HCC in the literature on 
the Iranian population. There are a few published 
papers about the epidemiology of HCC risk factors 
such as Hepatitis B  (7, 8) and Hepatitis C  (9) and 
their  geographic  distributions,  but  the  incidence 
and  geographical  pattern  of  HCC  are  not  clearly 
defined. The Iranian government’s Department for 
Fighting Cancer includes a cancer registry program, 
which published its first report in 1986. In 1999 the 
executive guidelines for cancer registry were revised 
and the second report was published; however, it is 
thought that the second report captured only 18% 
of new cases. The last report, which is based on data 
from 2005, is estimated to reflect around 80% of 
new cancer cases in the country (10). Kerman is a very 
wide province in southeast Iran, with a population 
of  approximately  2.6  million.  Traditionally,  the 
lifestyle of its inhabitants, such as their diet, might 
increase the risk of HCC. For instance, this province 
produces more than 60% of the country’s pistachios, 
which used to be a main source of dietary aflatoxin 
exposure. In addition, viral hepatitis used to be more 
or less common in this province, but generally not 
greater than the national average (8, 11). There are 
also  two  reports  about  the  prevalence  of  positive 
HBs  antigen  in  pregnant  women  in  the  Kerman 
province, and their estimated prevalence seems to 
be the same as the national figure (12, 13). Based on 
the above explanation, we explored the data from 
the national cancer registry and also the province’s 
population-based  registry  in  order  to  generate  an 
acceptable annual incidence risk of HCC in Kerman 
and compare this figure with the national incidence.
Materials and Methods
We  searched  all  databanks  of  cancer  cases 
extensively, including all pathology, oncology, and 
radiology centers and medical documents and death 
registries within the Kerman province between 1999 
and 2006. In this search, we extracted the data of all 
patients with any type of liver cancers to maximize 
our sensitivity to the detection of HCC. In addition, 
we searched the national cancer registry databank 
to find any possible Kermanian cases recorded in 
the data of other provinces. We excluded duplicate 
records by using the full names of cases. In order 
to compare the incidence of HCC in Kerman with 
the  incidence  in  other  areas  in  the  country,  the 
national  and  provincial  figures  in  a  few  selective 
provinces  were  extracted  from  the  cancer  registry 
database.  We  selected  six  provinces  because  they 
have the most complete data in their cancer registry 
databanks (Esfahan, Razavi Khorasan, Khoozestan, 
Golestan,  Ardebil,  West  Azerbaijan, Tehran,  Fars, 
and Guilan). Because we expect the cancer registry 
in these provinces to have maximum sensitivity, the 
estimated incidence in Kerman (data from different 
sources) is more comparable with the incidence in 
these selected provinces. 
The  data  were  computerized  using  CanReg 
Software  (produced  by  Iran’s  Ministry  of  Health 
through its cancer registry program). The statistical 
analysis was performed using Stata (version 8). The 
total populations of provinces and their age and sex 
distributions were extracted from the data from the 
Iranian national census in 2006. The Standardized 
incidence  of  HCC  was  calculated  at  both  the 
provincial and national levels using WHO’s world 
standard population. The 95% confidence intervals 
of the incidences were computed using a Poisson 
distribution  and  were  compared  using  a  Poisson 
regression model.
Results
We found the records of 333 cases labeled as liver 
tumor in Kerman between 1999 and 2006; among 
them, only 95 cases had confirmed HCC diagnosis; 
others were mostly metastases of other cancers to the 
liver. Only two new HCC cases were added to our 
records from the national cancer registry databank; 
these two cases sought their treatments outside of 
the Kerman province. The crude annual incidence 
risk in Kerman was 0.522 (95% CI = 0.283-0.88) 
per 100,000. After adjusting for age and sex, the 
standardized risk was 0.7 (95% CI = 0.4-1.1) per 
100,000. The  standardized  risk  in  males  was  0.9 
(0.3-1.5) and in females was 0.4 (0.0-0.8).  During 
2005-2006, 484 cases of liver tumors were recorded 
in the cancer registry database around the country. 
Among them, 279 records had a confirmed diagnosis 
of HCC. The crude annual incidence risk of HCC in 
Iran was 0.199 (95% CI = 0.167-0.234) per 100,000. 
After  adjusting  for  age  and  sex,  the  standardized 
risk was 0.2 (95% CI = 0.2-0.3) per 100,000. The Hepat Mon. 2010; 10(4): 270-274
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to the synergistic effect of aflatoxin and hepatitis in 
the development of HCC (18). However, due to some 
issues, such as improvements in people’s lifestyles, 
turning  attention  away  from  the  preservation  of 
high-quality pistachio, and clearer definitions “health 
programs” by the Health Ministry of Iran, people’s 
exposure to aflatoxin have decreased considerably in 
recent decades.
Some portion of the lower HCC incidence rate 
in Iran as a whole than in Kerman could be due 
to the low accuracy of the national cancer registry 
compared to the sensitivity of our multiple sources 
of active case findings in Kerman. However, because 
the diagnosis of HCC is not difficult, particularly 
in the advanced stages, we do not expect that this 
explanation by itself can explain such a wide difference 
between the incidence rates in Iran and Kerman. We 
also compared our estimates with those in provinces 
with high-quality cancer registries (Table 1), which 
showed  that  the  crude  annual  incidence  rate  of 
HCC in Kerman was the highest of all provinces. 
In addition, in order to minimize this error, we only 
used the data from the last 2 years to estimate the 
national incidence rate. In general, we expect that 
the quality of the national cancer registry has been 
improved in recent years. In conclusion, we believe 
that the incidence of HCC in Kerman is greater than 
the rate in the whole country, although the rate is 
still very low compared to the global figure. 
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